Incidence of DAA failure and the clinical impact of retreatment in real-life patients treated in the advanced stage of liver disease: Interim evaluations from the PITER networkLoreta A. Kondili, Stefano Vella, Francesco Paolo Russo et al.|PLoS ONE|2017Cited by 114
Real-life data on potential drug-drug interactions in patients with chronic hepatitis C viral infection undergoing antiviral therapy with interferon-free DAAs in the PITER Cohort StudyLoreta A. Kondili, Massimo Puoti, Giovanni Battista Gaeta et al.|PLoS ONE|2017Cited by 46
Forecasting Hepatitis C liver disease burden on real‐life data. Does the <i>hidden iceberg</i> matter to reach the elimination goals?Loreta A. Kondili, Sarah Robbins Scott, Sarah Blach et al.|Liver International|2018Cited by 45
A prospective study of direct‐acting antiviral effectiveness and relapse risk in HCV cryoglobulinemic vasculitis by the Italian PITER cohortLoreta A. Kondili, Anna Linda Zignego, Monica Monti et al.|Hepatology|2021Cited by 36
Modeling cost‐effectiveness and health gains of a “universal” versus “prioritized” hepatitis C virus treatment policy in a real‐life cohortLoreta A. Kondili, Federica Romano, Francesca Romana Rolli et al.|Hepatology|2017Cited by 29